Pharmaceutical firm Lupin yesterday said that it will acquire Japanese healthcare provider I'rom Pharmaceutical in order to enter into the generic injectables segment in Japan.
The proposed deal comes after the Mumbai-based pharmaceutical had acquired Japan's Kyowa Pharmaceutical Industry Co in 2007.
Lupin, which did not disclose the deal value, said that it expects I'rom Pharma sales to touch $75 million in the current financial year ending March 2012.
With 2010 sales of 5.36 billion yen ($69.7 million), and a fully-owned subsidiary of I'rom Holdings Co, I'rom Pharma is a specialty injectables company.
The Tokyo-based company's site management organisation (SMO) segment provides support services for clinical trial facilities.
The medical supports segment establishes and leases clinic complex facilities, as well as provides medical consulting and support services. The human resources consulting segment provides staffing services, such as nurses, pharmacists and other medical-related workers to medical institutions, as well as training and education services.